Discovery of 7-aryl-substituted (1,5-naphthyridin-4-yl)ureas as aurora kinase inhibitors. 2014

Julien Defaux, and Maud Antoine, and Marc Le Borgne, and Tilmann Schuster, and Irene Seipelt, and Babette Aicher, and Michael Teifel, and Eckhard Günther, and Matthias Gerlach, and Pascal Marchand
Université de Nantes, Nantes Atlantique Universités, Laboratoire de Chimie Thérapeutique, Cibles et Médicaments des Infections et du Cancer IICiMed EA 1155, UFR des Sciences Pharmaceutiques et Biologiques, 1 rue Gaston Veil, 44035 Nantes (France).

As part of our research projects to identify new chemical entities of biological interest, we developed a synthetic approach and the biological evaluation of (7-aryl-1,5-naphthyridin-4-yl)ureas as a novel class of Aurora kinase inhibitors for the treatment of malignant diseases based on pathological cell proliferation. 1,5-Naphthyridine derivatives showed excellent inhibitory activities toward Aurora kinases A and B, and the most active compound, 1-cyclopropyl-3-[7-(1-methyl-1H-pyrazol-4-yl)-1,5-naphthyridin-4-yl]urea (49), displayed IC₅₀ values of 13 and 107 nM against Aurora kinases A and B, respectively. In addition, the selectivity toward a panel of seven cancer-related protein kinases was highlighted. In vitro ADME properties were also determined in order to rationalize the difficulties in correlating antiproliferative activity with Aurora kinase inhibition. Finally, the good safety profile of these compounds imparts promising potential for their further development as anticancer agents.

UI MeSH Term Description Entries
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D009287 Naphthyridines A group of two-ring heterocyclic compounds consisting of a NAPHTHALENES double ring in which two carbon atoms, one per each ring, are replaced with nitrogens.
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014508 Urea A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. Basodexan,Carbamide,Carmol

Related Publications

Julien Defaux, and Maud Antoine, and Marc Le Borgne, and Tilmann Schuster, and Irene Seipelt, and Babette Aicher, and Michael Teifel, and Eckhard Günther, and Matthias Gerlach, and Pascal Marchand
April 2016, Archives of pharmacal research,
Julien Defaux, and Maud Antoine, and Marc Le Borgne, and Tilmann Schuster, and Irene Seipelt, and Babette Aicher, and Michael Teifel, and Eckhard Günther, and Matthias Gerlach, and Pascal Marchand
April 2013, Bioorganic & medicinal chemistry letters,
Julien Defaux, and Maud Antoine, and Marc Le Borgne, and Tilmann Schuster, and Irene Seipelt, and Babette Aicher, and Michael Teifel, and Eckhard Günther, and Matthias Gerlach, and Pascal Marchand
December 2021, Pharmaceuticals (Basel, Switzerland),
Julien Defaux, and Maud Antoine, and Marc Le Borgne, and Tilmann Schuster, and Irene Seipelt, and Babette Aicher, and Michael Teifel, and Eckhard Günther, and Matthias Gerlach, and Pascal Marchand
June 2010, Journal of medicinal chemistry,
Julien Defaux, and Maud Antoine, and Marc Le Borgne, and Tilmann Schuster, and Irene Seipelt, and Babette Aicher, and Michael Teifel, and Eckhard Günther, and Matthias Gerlach, and Pascal Marchand
April 2018, Bioorganic & medicinal chemistry letters,
Julien Defaux, and Maud Antoine, and Marc Le Borgne, and Tilmann Schuster, and Irene Seipelt, and Babette Aicher, and Michael Teifel, and Eckhard Günther, and Matthias Gerlach, and Pascal Marchand
February 2017, Journal of medicinal chemistry,
Julien Defaux, and Maud Antoine, and Marc Le Borgne, and Tilmann Schuster, and Irene Seipelt, and Babette Aicher, and Michael Teifel, and Eckhard Günther, and Matthias Gerlach, and Pascal Marchand
August 2017, Bioorganic & medicinal chemistry letters,
Julien Defaux, and Maud Antoine, and Marc Le Borgne, and Tilmann Schuster, and Irene Seipelt, and Babette Aicher, and Michael Teifel, and Eckhard Günther, and Matthias Gerlach, and Pascal Marchand
May 2012, Bioorganic & medicinal chemistry letters,
Julien Defaux, and Maud Antoine, and Marc Le Borgne, and Tilmann Schuster, and Irene Seipelt, and Babette Aicher, and Michael Teifel, and Eckhard Günther, and Matthias Gerlach, and Pascal Marchand
November 2014, Bioorganic & medicinal chemistry,
Julien Defaux, and Maud Antoine, and Marc Le Borgne, and Tilmann Schuster, and Irene Seipelt, and Babette Aicher, and Michael Teifel, and Eckhard Günther, and Matthias Gerlach, and Pascal Marchand
October 2017, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!